Major Pharma Short Interest Faces Significant Drop

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Major Pharma Short Interest Faces Significant Drop

© Thinkstock

The short interest data have been released for the August 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.

Drug prices may be under pressure due to the campaign rhetoric and under scrutiny, but if generic drugs are going to keep increasing in market share of existing drugs, then there would seem to be a reason for owning major pharmaceuticals.

The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.

[nativounit]

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

Pfizer Inc. (NYSE: PFE) saw its short interest decrease to 39.63 million shares from the previous 47.81 million. Shares of Pfizer closed Wednesday at $34.82, within a 52-week trading range of $28.25 to $37.39.

Merck & Co. Inc. (NYSE: MRK) had a rise in short interest to 31.29 million shares, from 28.37 million in the previous period. Its shares closed Wednesday at $62.73, in a 52-week range of $47.97 to $64.00.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest decreased to 13.80 million shares. The previous level was 20.81 million. Shares closed Wednesday at $51.63, in a 52-week range of $48.01 to $66.55.

Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest decrease to 9.65 million shares from the previous reading of 14.06 million. Shares closed Wednesday at $58.59, within a 52-week range of $56.32 to $77.12.

AbbVie Inc. (NYSE: ABBV) short interest fell to 48.00 million shares, compared to the previous 50.88 million. Shares of AbbVie closed Wednesday at $65.06, in a 52-week trading range of $45.45 to $68.12.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618